Telix Pharmaceuticals (ASX:TLX) developed and validated a generator technology to produce the lead-212 isotope for Targeted Alpha Therapy, completing its first production run, according to a Thursday statement.
The technology, created by Telix's IsoTherapeutics team, uses a sealed thorium-228 source, offering higher radioactivity, improved yield, and longer shelf life than the existing technology, overcoming lead-212 short half-life and production challenges, the statement said.
The automated generator produces up to 60 clinical doses per elution and can be scaled for broader production, the statement added.
Telix plans to expand this technology across its manufacturing and distribution networks, including the recently acquired RLS Radiopharmacies, the company said.
Shares of the company rose 1% in recent Friday trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。